Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InPedILD-ON long-term open-label safety study of nintedanib in pediatric fibrosing interstitial lung disease
2024-515743-27-00Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of nintedanib in childhood interstitial lung disease (chILD) and pulmonary fibrosis (PF), sponsored by Boehringer Ingelheim. Primary endpoint: Incidence of treatment-emergent adverse events. Started Apr 2022; status: completed.
02
Drugs
nintedanib
03
Conditions
childhood interstitial lung disease (chILD)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on 2024-515743-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515743-27-00.